Using nothing more than the smartphone camera, Mobio Interactive's proprietary computer vision and AI accurately and objectively measure stress in under 30 seconds.
Mobio Interactive rigorously interrogates the efficacy of its digital therapeutics.
Am Mindfulness is the first and only resilience app proven to outperform placebo.
Stress Resilience
In a landmark study, researchers found that MI's DTx produced "significant improvement" in stress resilience amongst university students self-reporting issues with anxiety, when compared to placebo.
In landmark study, researcher found that MI's DTx produced "long-term benefits for attentional control," compared to placebo, indicating that MI's app Am Mindfulness can enhance focus in university students.
In a clinical trial with urban and rural cancer survivors, Am Mindfulness provides stress reductions "similar in effect sizes of in-person programs," indicating medical-grade stress relief is now accessible to cancer patients regardless of their location.
In a clinical trial with cancer patients, researchers are investigating the potential for Am Mindfulness to reduce the "fear of cancer recurrence," something which is often a very serious burden on cancer survivors and their loved ones.
Researchers examined the mental response to HIE (High Intensity Exercise) in amature athletes who trained with Am Mindfulness versus a control app, and have found some intriguing results important for exercise paradigm adherence.
Some of our ongoing research in patient populations is currently confidential, but we're committed to disseminating the results as soon as possible, for the benefit of patients as well as the entire DTx industry around the world.
Interested in conducting a trial? Just let us know.
